A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus

Inclusion Criteria: Subjects with known Barrett's Esophagus (BE). * Patients with a BE segment ≥ 1cm in maximal extent endoscopically. * Histology showing evidence of intestinal metaplasia with or without presence of dysplasia. * Undergoing clinically indicated endoscopy. Subjects without known evidence of BE - Undergoing clinically indicated diagnostic endoscopy Exclusion Criteria: * Subjects with known BE. * Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic mucosal resection alone will not be excluded. * Patients with history of esophageal resection for esophageal carcinoma. Subjects with or without known evidence of BE (on history or review of medical records). * Pregnant or lactating females. * Patients who are unable to consent. * Patients with current history of eosinophilic esophagitis, achalasia or uninvestigated dysphagia. * Patients on oral anticoagulation including Coumadin, Warfarin. * Patients on antiplatelet agents including Clopidogrel, unless discontinued for 3 days prior to the sponge procedure. * Patients on oral thrombin inhibitors including Dabigatran and oral factor X a inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for 3 days prior to the sponge procedure. * Patients with history of known varices or cirrhosis. * Patients with history of esophageal resection for esophageal carcinoma. * Patients with congenital or acquired bleeding diatheses. * Patients with a history of esophageal squamous dysplasia. * Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.